Repotrectinib is a new generation of targeted anticancer drug developed by Bristol-Myers Squibb (BMS), providing a new option for precision treatment for patients with advanced cancer! It was approved for marketing by the US FDA in November 2023.
Repotrectinib Side Effects
Common Adverse Reactions (Incidence ≥20%)
During treatment with Repotrectinib, dizziness, taste disturbances, peripheral neuropathy, constipation, dyspnea, fatigue, ataxia, cognitive impairment, muscle weakness, and nausea may occur.
Repotrectinib Side Effects for Medical Personnel Reference
General Adverse Reactions
(1) The most frequently reported side effects of Repotrectinib include ataxia, cognitive impairment, constipation, dizziness, taste disturbances, dyspnea, fatigue, nausea, and peripheral neuropathy.
(2) The most frequently reported grade 3 or 4 laboratory abnormalities include decreased hemoglobin, leukopenia, lymphopenia, neutropenia, decreased phosphate, decreased sodium, elevated alanine aminotransferase (ALT), elevated alkaline phosphatase, elevated aspartate aminotransferase (AST), elevated creatine phosphokinase, elevated gamma-glutamyl transferase (GGT), elevated glucose, elevated magnesium, and elevated uric acid.
Cardiovascular System:
Frequency not reported: cardiac arrest, heart failure, sudden cardiac death, sudden death.
Gastrointestinal System:
Very common (10% and above): constipation (up to 37%), nausea (up to 20%), diarrhea (up to 13%), vomiting (10%).
Hematologic System:
Very common (10% and above): Decreased hemoglobin (up to 73%), lymphopenia (up to 43%), leukopenia (up to 36%), neutropenia (up to 34%), prolonged activated partial thromboplastin time (up to 25%), elevated prothrombin international normalized ratio (up to 20%).
Not reported frequency:
Disseminated intravascular coagulation (DIC).
Liver:
Very common (10% and above): Elevated gamma-glutamyl transferase (GGT) (up to 48%), elevated aspartate aminotransferase (AST) (up to 40%), elevated alanine aminotransferase (ALT) (up to 35%).
Not reported frequency: Hepatotoxicity.
Metabolic System:
Very common (10% and above): Elevated glucose (up to 23%), elevated uric acid (up to 21%).
Common (1% to 10%): Hyperuricemia.
Musculoskeletal System
Very common (10% and above): Elevated creatine phosphokinase (up to 57%), muscle weakness (up to 21%), myalgia (up to 13%).
Common (1% to 10%): Bone fractures.
Myalgia includes myalgia, myositis, musculoskeletal discomfort, and musculoskeletal pain.
Nervous System
Very common (10% and above): Central nervous system (CNS) adverse reactions (up to 75%), dizziness (up to 64%), taste disturbances (up to 50%), peripheral neuropathy (up to 47%), ataxia (up to 29%), cognitive impairment (up to 23%), headache (up to 19%), memory impairment (13%), attention deficit (11%).
Common (1% to 10%): Central nervous system toxicity, somnolence, excessive somnolence.
Frequency not reported:
(1) Tremor. Dizziness includes vertigo, vertigo, postural dizziness, exertional dizziness, and positional vertigo.
(2) Taste disorders include taste disorders, loss of taste, loss of smell, and hypotaste.
(3) Peripheral neuropathy includes neuralgia, peripheral neuropathy, peripheral sensory neuropathy, paresthesia, peripheral motor neuropathy, polyneuropathy, paresthesia, hypotasteia, and hyperesthesia.
(4) Ataxia includes ataxia, gait disturbance, balance disorder, and cerebellar ataxia.
(5) Cognitive impairment includes memory impairment, attention deficit, cognitive impairment, confusion, amnesia, attention deficit hyperactivity disorder, delirium, altered state of consciousness, aphasia, delusions, decreased level of consciousness, hallucinations, altered mental state, and neurological decompensation.
(6) Headache includes headache, migraine, and tension headache.
Eye problems:
Very common (10% and above): Visual impairment (up to 11%).
Visual disturbances include blurred vision, dry eye, visual impairment, visual field defects, cataracts, conjunctivitis, eye pain, photophobia, photosensitivity, decreased vision, vitreous opacity, blepharospasm, color blindness, diplopia, ocular hematoma, eye swelling, eyelid disorders, eyelid injury, eyelid pruritus, glaucoma, night blindness, and ocular herpes zoster.
Mental health:
Common (1% to 10%): confusion, mood disorders, insomnia, anxiety, irritability, depression.
Respiratory system:
Very common (10% and above): dyspnea (up to 30%), cough (up to 14%).
Common (1% to 10%): pneumonia, pleural effusion, hypoxia, pneumonia.
Uncommon (0.1% to 1%): interstitial lung disease.
Not reported frequency: aspiration pneumonia, respiratory failure.
Dyspnea includes dyspnea and exertional dyspnea. Cough includes sputum production, cough, and upper airway cough syndrome.
Other:
Very common (10% and above): fatigue (up to 29%), elevated sodium (up to 29%), elevated alkaline phosphatase (up to 26%), decreased glucose (up to 21%), weight gain (up to 14%), edema (up to 12%).
Common (1% to 10%): decreased phosphate, decreased sodium, falls, elevated magnesium, fever.
Not reported frequency: death. Fatigue includes fatigue and weakness. Edema includes generalized edema, periorbital edema, localized edema, facial edema, peripheral edema, edema, ocular edema, and scrotal edema.
